Bio-pharma innovation heavily relies on animal testing, despite the significant financial implications. Preclinical spending continues to grow, while drug markets have become increasingly niche. To bridge the gap between in vivo modeling in large animals and R&D of therapeutic drugs as well as gene therapy strategies, Gentas BioTech utilizes novel technologies and platforms. These animal models from Gentas can help predict clinical success earlier in the development process.
Predictive Minipig Platform
Proprietary Disease Models
● Well characterized minipigs
● Compliant with FDA, NMPA, GLP, SPF and AAALAC standards
● Ongoing studies with 4 companies
● Mimicking complex conditions
· Psoriasis
· Beethoven heaing loss
● Demonstrated track record – 2 disease models
phenotyped, 13 in the pipeline
● Strategic partnerships
Animal Models
Animal experiments play a vital role in the research and development of new drugs. Providing an important pillar for pharmacological and toxicological analysis of new drugs, preclinical evaluation of efficacy, IND cases, and the design and implementation of clinical trials.
Services
Therapeutic Areas
1. POC
2. Efficacy Studies
3. PK/PD
4. Toxicology
5. Surgical Training
6. Medical Device Testing
1. Cardiovascular
2. Digestive system
3. Liver, gallbladder, pancreas
4. Skin disorders
5. Oncology
6. Diabetes
7. Osteoporosis
8. Obesity
Currently under final stage of construction, our state-of-the-art experimental facility, spanning 5500 square meters (m²) or approximately 60,000 square feet (ft²), is situated within the Zhangjiang Hi-Tech Park in jinshan City, Shanghai.
The facility is designed to accommodate approximately 200 cages, adhering to AAALAC standards. lt features conventional (CV), specific pathogen-free (SPF), and Animal Biosafety Level 2 (ABSL-2) areas, catering to a diverse range of research needs. Additionally, it is equipped with in vitro supporting laboratories encompassing molecular/cell biology, clinical testing, pathology, analytics, and formulation, among others.
Our facility strictly follows international standards in all operations, animal welfare practices, Environmental Health and Safety (EHS), Quality Control (QC), and experimental procedures. This commitment ensures the highest quality of experiments, consistency, and accuracy of experimental data, while ensuring timely delivery.
Our Facility
Chief Scientific Officer
Dr. Jianguo Zhao
• 10+ years of experience in gene
editing & swine models for human
biomedical research
• Ph.D. in Animal genetics and
breeding from Northeast
Agricultural University. Postdoc in
University of New Orleans
• Assistant professor at University of
Missouri-Columbia and at the
National Swine Research and
Resource Center
Chief Technical Officer
Dr. Liangxue Lai
• Internationally recognized expert
in large animal cloning, transgenic
and gene-editing technology
• Professor in Guangzhou Institute of
Biomedical and Health, CAS & in
Jilin University.
• Established more than 50
transgenic & gene targeted large
animal models for biomedicine and
agriculture
Our Management Team
Contact Information
Gentas Biotechnology Co., Ltd
Tel.: (+86) 021-58815808
Email: Info@gentasbiotech.com
Room1406, No.515 , Huanke Road, Pudong District, Shanghai
Johnson & Johnson Innovation
JLABS @ Shanghai
5th Flour, No.1 South Building, No.4560 Jinke Road, Pudong District, Shanghai
Main Experimental Platform
Floor 1 & 3, North Building Two, No. 857,
Tian Gong Road, Jin ShanDistrict,
Copyright Gentas Biotechnology 2024 – All Rights Reserved
On the morning of September 7, 2023, the opening ceremony of the experimental platform project of Jinyue Biotechnology Co., Ltd. was officially held in Zhangjiang Jinshan Biomedical Industrial Park. At this point, the experimental platform of Jinyue Biotechnology officially started construction.
Gentas has hired a number of world-renowned experts in large animal cloning, transgenic/targeting technology, animal models and new drug development to establish a scientific advisory committee.
our platform and technology will greatly accelerate the clinical transformation of new drug research and development and replace the use of dogs and primates in experiments.
the development of SPF and internationally certified large animal experiment platforms to provide key preclinical data and POC proof of concept required for clinical trials of new drugs.
News
Scientific Literature